Active, Not Recruiting
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
NCT04835805
- Conditions
- Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
- Locations
-
- California Pacific Medical Center Research Institute San Francisco, California, United States
- UCSF Helen Diller Family CCC San Francisco, California, United States
- University of Colorado Cancer Center Aurora, Colorado, United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States